pe vio770 Search Results


94
Miltenyi Biotec anti cd62l pe vio770
Anti Cd62l Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd62l pe vio770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cd62l pe vio770 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd19 pe vio770
Cd19 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd19 pe vio770/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd19 pe vio770 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd69 pe vio 770
Cd69 Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd69 pe vio 770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd69 pe vio 770 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec pe vio 770
Pe Vio 770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe vio 770/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
pe vio 770 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd40
Effect of anti‐CD52‐Ab treatment on the phenotype of periphery innate immune cells in EAE mice at first day post‐injection. Single‐cell suspensions were obtained from blood and spleen tissue of anti‐CD52‐Ab or vehicle‐treated EAE mice at first day after the final dose injection. Cells were stained for various surface markers and analysed by flow cytometry. (A) Flow cytometry gating strategy. (B) Blood and spleen CD11c + cells were analysed for expression of MHC‐II ( n = 9), <t>CD40</t> ( n = 5), CD80 ( n = 5) and CD86 ( n = 9 blood; n = 5 spleen). (C) Blood and spleen CD11b + cells were analysed for expression of MHC‐II ( n = 8), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5), CD38 ( n = 5) and CD206 ( n = 9 blood; n = 7 spleen). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001
Cd40, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd40/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd40 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd68 pe vio770
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Cd68 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd68 pe vio770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd68 pe vio770 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

95
Miltenyi Biotec cd3 pe vio770
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Cd3 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd3 pe vio770/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd3 pe vio770 - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier

96
Miltenyi Biotec pe vio770 rea737 miltenyi biotec 130 110 661 anti mouse f4 80
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Pe Vio770 Rea737 Miltenyi Biotec 130 110 661 Anti Mouse F4 80, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe vio770 rea737 miltenyi biotec 130 110 661 anti mouse f4 80/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
pe vio770 rea737 miltenyi biotec 130 110 661 anti mouse f4 80 - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

97
Miltenyi Biotec surface antibody cd34 pe vio770
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Surface Antibody Cd34 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/surface antibody cd34 pe vio770/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
surface antibody cd34 pe vio770 - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier

94
Miltenyi Biotec pe vio770
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe vio770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
pe vio770 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec pe vio 771 conjugated anti cd63
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Pe Vio 771 Conjugated Anti Cd63, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe vio 771 conjugated anti cd63/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
pe vio 771 conjugated anti cd63 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

94
Miltenyi Biotec cd335 nkp46 pe vio770
Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, <t>CD68,</t> CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.
Cd335 Nkp46 Pe Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd335 nkp46 pe vio770/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
cd335 nkp46 pe vio770 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


Effect of anti‐CD52‐Ab treatment on the phenotype of periphery innate immune cells in EAE mice at first day post‐injection. Single‐cell suspensions were obtained from blood and spleen tissue of anti‐CD52‐Ab or vehicle‐treated EAE mice at first day after the final dose injection. Cells were stained for various surface markers and analysed by flow cytometry. (A) Flow cytometry gating strategy. (B) Blood and spleen CD11c + cells were analysed for expression of MHC‐II ( n = 9), CD40 ( n = 5), CD80 ( n = 5) and CD86 ( n = 9 blood; n = 5 spleen). (C) Blood and spleen CD11b + cells were analysed for expression of MHC‐II ( n = 8), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5), CD38 ( n = 5) and CD206 ( n = 9 blood; n = 7 spleen). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Journal: Immunology

Article Title: Anti‐CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems

doi: 10.1111/imm.13437

Figure Lengend Snippet: Effect of anti‐CD52‐Ab treatment on the phenotype of periphery innate immune cells in EAE mice at first day post‐injection. Single‐cell suspensions were obtained from blood and spleen tissue of anti‐CD52‐Ab or vehicle‐treated EAE mice at first day after the final dose injection. Cells were stained for various surface markers and analysed by flow cytometry. (A) Flow cytometry gating strategy. (B) Blood and spleen CD11c + cells were analysed for expression of MHC‐II ( n = 9), CD40 ( n = 5), CD80 ( n = 5) and CD86 ( n = 9 blood; n = 5 spleen). (C) Blood and spleen CD11b + cells were analysed for expression of MHC‐II ( n = 8), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5), CD38 ( n = 5) and CD206 ( n = 9 blood; n = 7 spleen). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Article Snippet: To block non‐specific Fc receptors, cells were resuspended in anti‐mouse CD16/CD32 Fc block (eBioscience) for 10 min before incubation with the appropriate antibodies against: CD11b (#130‐113‐236), CD11c (#130‐102‐545), CD38 (#130‐109‐257), CD40 (#130‐105‐376 or #130‐102‐533), CD80 (#130‐116‐465), CD86 (#130‐105‐137), MHC‐II (#130‐107‐942), all were purchased from MACS Miltenyi Biotec; and CD45 (#11‐0451‐82) and CD206 (#12‐2061‐82), all were purchased from Thermo Fisher Scientific.

Techniques: Injection, Staining, Flow Cytometry, Expressing, Two Tailed Test

Effect of anti‐CD52‐Ab treatment on the phenotype and function of CNS innate immune cells in EAE mice at first day post‐injection. Single‐cell suspensions were obtained from CNS (brain and spinal cord) tissue of anti‐CD52‐Ab or vehicle‐treated EAE mice at first day after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Flow cytometry gating strategy. (B) CD11b + CD45 lo/neg resident microglia and (C) CNS CD11b + CD45 hi infiltrating macrophages and were analysed for expression of MHC‐II ( n = 10), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5 microglia; n = 9 macrophages) and CD206 ( n = 7 microglia; n = 5 macrophages). Unpaired two‐tailed Student's t test. CD11b + cells were isolated from CNS tissue of anti‐CD52‐Ab or vehicle‐treated mice at first day after the final treatment dose. (D) Respiratory burst activity of CD11b + ‐isolated cells. (E) Phagocytosis of FITC‐coated beads by CD11b + isolated cells. Unpaired two‐tailed Student's t test. (F) Cells were left unstimulated or were stimulated with LPS or Poly(I:C)(PIC) for 24 h and cytokine production determined by ELISA. Two‐way ANOVA with Sidak multiple comparisons test, * p < 0·05, ** p < 0·01, *** p < 0·001

Journal: Immunology

Article Title: Anti‐CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems

doi: 10.1111/imm.13437

Figure Lengend Snippet: Effect of anti‐CD52‐Ab treatment on the phenotype and function of CNS innate immune cells in EAE mice at first day post‐injection. Single‐cell suspensions were obtained from CNS (brain and spinal cord) tissue of anti‐CD52‐Ab or vehicle‐treated EAE mice at first day after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Flow cytometry gating strategy. (B) CD11b + CD45 lo/neg resident microglia and (C) CNS CD11b + CD45 hi infiltrating macrophages and were analysed for expression of MHC‐II ( n = 10), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5 microglia; n = 9 macrophages) and CD206 ( n = 7 microglia; n = 5 macrophages). Unpaired two‐tailed Student's t test. CD11b + cells were isolated from CNS tissue of anti‐CD52‐Ab or vehicle‐treated mice at first day after the final treatment dose. (D) Respiratory burst activity of CD11b + ‐isolated cells. (E) Phagocytosis of FITC‐coated beads by CD11b + isolated cells. Unpaired two‐tailed Student's t test. (F) Cells were left unstimulated or were stimulated with LPS or Poly(I:C)(PIC) for 24 h and cytokine production determined by ELISA. Two‐way ANOVA with Sidak multiple comparisons test, * p < 0·05, ** p < 0·01, *** p < 0·001

Article Snippet: To block non‐specific Fc receptors, cells were resuspended in anti‐mouse CD16/CD32 Fc block (eBioscience) for 10 min before incubation with the appropriate antibodies against: CD11b (#130‐113‐236), CD11c (#130‐102‐545), CD38 (#130‐109‐257), CD40 (#130‐105‐376 or #130‐102‐533), CD80 (#130‐116‐465), CD86 (#130‐105‐137), MHC‐II (#130‐107‐942), all were purchased from MACS Miltenyi Biotec; and CD45 (#11‐0451‐82) and CD206 (#12‐2061‐82), all were purchased from Thermo Fisher Scientific.

Techniques: Injection, Staining, Flow Cytometry, Expressing, Two Tailed Test, Isolation, Activity Assay, Enzyme-linked Immunosorbent Assay

Effect of anti‐CD52‐Ab treatment on the phenotype of periphery and CNS innate immune cells in EAE mice at three weeks post‐injection. Single‐cell suspensions were obtained from blood, spleen and CNS (brain and spinal cord) tissue of anti‐CD52‐Ab or vehicle‐treated mice three weeks after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Blood and spleen CD11c + cells were analysed for expression of MHC‐II ( n = 9), CD40 ( n = 5), CD80 ( n = 5) and CD86 ( n = 9 blood; n = 5 spleen). (B) Blood and spleen CD11b + cells were analysed for expression of MHC‐II ( n = 8), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5), CD38 ( n = 5) and CD206 ( n = 9 blood; n = 7 spleen). (C) CNS CD11b + CD45 hi ‐infiltrating macrophages and CD11b + CD45 lo/neg resident microglia were analysed for expression of MHC‐II ( n = 10), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5 microglia; n = 9 macrophages) and CD206 ( n = 7 microglia; n = 5 macrophages). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Journal: Immunology

Article Title: Anti‐CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems

doi: 10.1111/imm.13437

Figure Lengend Snippet: Effect of anti‐CD52‐Ab treatment on the phenotype of periphery and CNS innate immune cells in EAE mice at three weeks post‐injection. Single‐cell suspensions were obtained from blood, spleen and CNS (brain and spinal cord) tissue of anti‐CD52‐Ab or vehicle‐treated mice three weeks after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Blood and spleen CD11c + cells were analysed for expression of MHC‐II ( n = 9), CD40 ( n = 5), CD80 ( n = 5) and CD86 ( n = 9 blood; n = 5 spleen). (B) Blood and spleen CD11b + cells were analysed for expression of MHC‐II ( n = 8), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5), CD38 ( n = 5) and CD206 ( n = 9 blood; n = 7 spleen). (C) CNS CD11b + CD45 hi ‐infiltrating macrophages and CD11b + CD45 lo/neg resident microglia were analysed for expression of MHC‐II ( n = 10), CD40 ( n = 5), CD80 ( n = 5), CD86 ( n = 5 microglia; n = 9 macrophages) and CD206 ( n = 7 microglia; n = 5 macrophages). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Article Snippet: To block non‐specific Fc receptors, cells were resuspended in anti‐mouse CD16/CD32 Fc block (eBioscience) for 10 min before incubation with the appropriate antibodies against: CD11b (#130‐113‐236), CD11c (#130‐102‐545), CD38 (#130‐109‐257), CD40 (#130‐105‐376 or #130‐102‐533), CD80 (#130‐116‐465), CD86 (#130‐105‐137), MHC‐II (#130‐107‐942), all were purchased from MACS Miltenyi Biotec; and CD45 (#11‐0451‐82) and CD206 (#12‐2061‐82), all were purchased from Thermo Fisher Scientific.

Techniques: Injection, Staining, Flow Cytometry, Expressing, Two Tailed Test

Effect of anti‐CD52‐Ab treatment on the function of periphery and CNS innate immune cells in SCID mice at first day post‐injection. SCID mice were treated with either vehicle or 10 mg/kg murine anti‐CD52‐Ab‐Ab for five consecutive days. Single‐cell suspensions were then obtained from blood and spleen tissues first day after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Blood and spleen CD11c + cells were analysed for expression of MHC‐II, CD40, CD80 and CD86 (all n = 7). (B) Blood and spleen CD11b + cells were analysed for expression of MHC‐II, CD40, CD80, CD86, and CD206 (all n = 7). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Journal: Immunology

Article Title: Anti‐CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems

doi: 10.1111/imm.13437

Figure Lengend Snippet: Effect of anti‐CD52‐Ab treatment on the function of periphery and CNS innate immune cells in SCID mice at first day post‐injection. SCID mice were treated with either vehicle or 10 mg/kg murine anti‐CD52‐Ab‐Ab for five consecutive days. Single‐cell suspensions were then obtained from blood and spleen tissues first day after the final treatment dose. Cells were stained for various surface markers and analysed by flow cytometry. (A) Blood and spleen CD11c + cells were analysed for expression of MHC‐II, CD40, CD80 and CD86 (all n = 7). (B) Blood and spleen CD11b + cells were analysed for expression of MHC‐II, CD40, CD80, CD86, and CD206 (all n = 7). Unpaired two‐tailed Student's t test. * p < 0·05, ** p < 0·01, *** p < 0·001

Article Snippet: To block non‐specific Fc receptors, cells were resuspended in anti‐mouse CD16/CD32 Fc block (eBioscience) for 10 min before incubation with the appropriate antibodies against: CD11b (#130‐113‐236), CD11c (#130‐102‐545), CD38 (#130‐109‐257), CD40 (#130‐105‐376 or #130‐102‐533), CD80 (#130‐116‐465), CD86 (#130‐105‐137), MHC‐II (#130‐107‐942), all were purchased from MACS Miltenyi Biotec; and CD45 (#11‐0451‐82) and CD206 (#12‐2061‐82), all were purchased from Thermo Fisher Scientific.

Techniques: Injection, Staining, Flow Cytometry, Expressing, Two Tailed Test

Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.

Journal: Translational Oncology

Article Title: Adipose tissue from oesophageal adenocarcinoma patients is differentially affected by chemotherapy and chemoradiotherapy regimens altering immune cell phenotype and cancer cell metabolism

doi: 10.1016/j.tranon.2025.102302

Figure Lengend Snippet: Chemoradiotherapy treated adipose secretome significantly increases immunoinhibitory markers TIM-3 on unpolarised Mɸ. A-L) Expression of unpolarised Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86, CD80+CD86+, CD163, CD206, and CD163+CD206+ following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). L) PCA analysis of Mɸs polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.

Article Snippet: Antibodies used for Mɸ staining included CD11b-FITC, CD11c-Vio-Blue, CD80-PE, CD206-APC-Vio770, CD86-PerCp-Vio700, HLA-DR-Vio-Green, TIM-3-APC, CD68-PE-Vio770, and CD163-PEVio615 (Miltenyi, Germany).

Techniques: Expressing, Marker, Comparison

Chemotherapy treated adipose secretome significantly increases M1 polarised Mɸ expression of phenotypic and immune-inhibitory ligands whilst the chemoradiotherapy treated adipose secretome increases M2 polarised Mɸ expression of CD206. A-I) Expression of LPS M1 primed Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86 as well as co-expression of CD80 and CD86 following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). J) PCA analysis of M1-primed Mɸ polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. K-S) Expression of IL-4 M2 primed Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD163, CD206 as well as co-expression of CD163 and CD206 following exposure to chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). T) PCA analysis of M2-primed Mɸ polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.

Journal: Translational Oncology

Article Title: Adipose tissue from oesophageal adenocarcinoma patients is differentially affected by chemotherapy and chemoradiotherapy regimens altering immune cell phenotype and cancer cell metabolism

doi: 10.1016/j.tranon.2025.102302

Figure Lengend Snippet: Chemotherapy treated adipose secretome significantly increases M1 polarised Mɸ expression of phenotypic and immune-inhibitory ligands whilst the chemoradiotherapy treated adipose secretome increases M2 polarised Mɸ expression of CD206. A-I) Expression of LPS M1 primed Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD80, CD86 as well as co-expression of CD80 and CD86 following exposure to untreated, chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). J) PCA analysis of M1-primed Mɸ polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. K-S) Expression of IL-4 M2 primed Mɸ phenotypic and immunoinhibitory markers including viability, CD68, CD11b, CD11c, HLA-DR, TIM-3, CD163, CD206 as well as co-expression of CD163 and CD206 following exposure to chemotherapy treated (FLOT) and chemoradiotherapy treated (CROSS) adipose conditioned media, (Friedman test with Dunn's correction). T) PCA analysis of M2-primed Mɸ polarisation marker expression following culture with the treated adipose secretome through dimensionality reduction. All data expressed as mean ± SEM, n = 6, associated p-value displayed above comparison, only signifcant results shown.

Article Snippet: Antibodies used for Mɸ staining included CD11b-FITC, CD11c-Vio-Blue, CD80-PE, CD206-APC-Vio770, CD86-PerCp-Vio700, HLA-DR-Vio-Green, TIM-3-APC, CD68-PE-Vio770, and CD163-PEVio615 (Miltenyi, Germany).

Techniques: Expressing, Marker, Comparison